Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Campbell Soup Co. (CPB) vs Medpace Holdings Inc (MEDP) Price & Performance

Campbell Soup Co.Trade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Campbell Soup Co. vs Medpace Holdings Inc — how do they compare? Campbell Soup Co. trades at $22.66 (market cap $6.78B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 2.5× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays a 6.87% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

CPBMEDP
Market Cap
$6.78B$16.90B
Sector
Consumer StaplesTechnology
52-Week High
$34.03$620.59
52-Week Low
$20.00$393.42
Enterprise Value
$13.38B$16.52B
Dividend Yield
6.87%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Campbell Soup Co.

Campbell's (CPB) trades at $22.61, up 0.85% with a bullish technical signal. The company shows stable revenue around $10B but faces margin pressure with net income margin at 6.12%. Recent earnings have been mixed with Q2 2026 results pending. Valuation appears reasonable with P/E of 11.14 and P/S of 0.68. The stock offers a dividend yield around 7%, supported by ongoing product innovation including new protein soups and gluten-free options.

CPB presents a value opportunity with attractive dividend yield but faces execution risks amid margin challenges. Analyst consensus remains cautious with 58.6% hold ratings. The key catalyst is successful implementation of cost-saving initiatives and portfolio rebalancing to improve profitability. Near-term performance depends on Q2 earnings results and consumer spending trends.

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Campbell Soup Co.

With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.

Read more on CPB

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP